-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Tag Archives: Birth Control Pills
Introvale levonorgestrel and ethinyl estradiol Tablets Recall
Translation Introvale (levonorgestrel and ethinyl estradiol) Tablets: Recall – Packaging Flaw AUDIENCE: Consumer, Pharmacy ISSUE: Sandoz notified the public that it issued a voluntary recall of 10 lots of its generic oral contraceptive Introvale in the US, following a recent … Continue reading
Posted in Consumer Products, FDA 2012, FDA Recall, Pharmacy
Tagged Birth Control Pills, Consumer, Consumer Products, drug risks, ethinyl estradiol, extended-cycle oral contraceptive, Family Practice, FDA recall, Introvale, Introvale levonorgestrel and ethinyl estradiol Tablets Recall, levonorgestrel, Pharmacy, Recall, Sandoz, tablets
Comments Off
Birth Control Pills Health Risks
TranslationBirth Control Pills Containing Drospirenone: Label Change-Products may be associated with a higher risk for blood clots AUDIENCE: OBGYN, Family Practice, Patient ISSUE: FDA has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots … Continue reading
Posted in Family Practice, FDA 2012, FDA Label Change, OBGYN, Patients
Tagged Birth Control Pills, Birth Control Pills Health Risks, Drospirenone, drug risks, Family Practice, FDA notice, Health Risks, higher risk for blood clots, OBGYN, safety label changes
Comments Off
Norgestimate and Ethinyl Estradiol Tablets Recall
TranslationNorgestimate and Ethinyl Estradiol Tablets: Recall – Packaging Error, Potential for Incorrect Dosing Regimen AUDIENCE: OB/GYN, Pharmacy, Patient ISSUE: Glenmark Generics Inc. issued a nationwide, consumer-level recall of seven (7) lots of Norgestimate and Ethinyl Estradiol Tablets USP (0.18 mg/0.035 … Continue reading
Posted in OBGYN, Pharmacy
Tagged Birth Control Pills, Dietary Supplements, drug risks, Ethinyl Estradiol Tablets, Family Practice, FDA recall, Norgestimate, Norgestimate and Ethinyl Estradiol Tablets Recall, OBGYN, Oral Contraceptives, Packaging Error, Patient, Pharmacy, Recall
Comments Off
Pfizer Birth Control Pills Lo Ovral 28 Recall
TranslationPfizer Birth Control Lo/Ovral-28 (Norgestrel/EthinylEstradiol) Tablets: Recall – Possibility of Inexact Tablet Counts or Out of Sequence Tablets AUDIENCE: OB/GYN, Healthcare Professionals, Consumers ISSUE: Pfizer Inc. notified healthcare professionals and consumers that it recalled 14 lots of Lo/Ovral-28 (norgestrel and … Continue reading
Posted in Consumer Products, FDA 2012, FDA Recall, Healthcare Professionals, OBGYN
Tagged Birth Control Pills, Consumers, drug risks, Family Practice, FDA recall, Healthcare Professionals, Lo Ovral 28, OBGYN, Pfizer, Pfizer Birth Control Pills Lo Ovral 28, Pharmacy, Recall
Comments Off